Cronos Group (CRON) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evolus (EOLS) has outperformed Cronos Group (CRON) over the past year, gaining 25.6% versus a gain of 20.1%. Over five years, EOLS leads with a +1.7% price change compared with -41.2% for CRON. Cronos Group is the larger company by market cap ($1.19 billion vs $515.2 million), about 2.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | EOLS |
|---|---|---|
| Share price | $3.22 | $7.80 |
| Market cap | $1.19B | $515.19M |
| 1-day change | -0.62% | +0.78% |
| YTD return | +22.43% | +17.29% |
| 1-year return | +20.15% | +25.60% |
| 5-year return | -41.24% | +1.69% |
| P/E ratio (TTM) | 16.95 | — |
| Forward P/E | — | 26.67 |
| EPS (TTM) | $0.19 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.61 | $9.31 |
| 52-week low | $2.28 | $3.86 |
| Distance from 52-week high | -10.75% | -16.22% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | -23.29% | +92.31% |
| Average volume | 1.13M | 900.79K |
| Shares outstanding | 368.41M | 66.05M |
| Employees | 610 | 353 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cronos Group is about 2.3 times larger than Evolus by market value ($1.19B vs $515.19M).
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Healthcare · Drug Manufacturers - Specialty & Generic · 610 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Healthcare · Drug Manufacturers - Specialty & Generic · 353 employees
CRON vs EOLS FAQ
Which is bigger, Cronos Group or Evolus?
Cronos Group (CRON) is larger, with a market capitalization of $1.19B compared with $515.19M for Evolus (EOLS).
Which stock has performed better over the past year, CRON or EOLS?
EOLS returned +25.60% over the past 12 months, compared with +20.15% for CRON (price return, excluding dividends). Past performance does not predict future results.
Are Cronos Group and Evolus in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.